22-gene signature predicts response to chemotherapy in a broad range of breast cancer subtypes

Only 15-25% of breast cancer patients from all histopathological subtypes currently respond to primary chemotherapy with a complete pathological response (pCR) and there is currently no test in widespread clinical use to predict whether a patient will respond. Here we present results describing a 22-gene signature that can identify breast cancer patients who will respond to taxol-combination chemotherapy in a wide range of molecular subtypes. The signature was identified using a biology-driven approach.

Click here to view abstract.

2018-04-20T05:49:05+00:00